Last reviewed · How we verify
NCT03035461: PANDA
Patient's Feelings After Receiving a Diagnosis of Age-related Macular Degeneration
trial in Age Related Macular Degeneration in 250 participants. Completed in 19 October 2018.
1 February 2018
Quick facts
| Lead sponsor | Centre Hospitalier Intercommunal Creteil |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 250 |
| Start date | 15 March 2017 |
| Primary completion | 1 February 2018 |
| Estimated completion | 19 October 2018 |
| Sites | 1 location across France |
Conditions studied
- Age Related Macular Degeneration — all drugs for Age Related Macular Degeneration →
Sponsor
Centre Hospitalier Intercommunal Creteil
Who can join
55 and older, any sex, with Age Related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly population of the industrialized world. AMD is a progressive degenerative disease affecting the central area of the retina, responsible for distinct vision. Vision loss arises from aberrant new vessel growth which causes the accumulation of blood or fluid within the retina's thickness and eventually leads to permanent scarring. The two major forms of AMD are exudative, or neovascular or "wet", and non-exudative, or "dry". Vascular endothelial growth factor (VEGF) represents the key modulator of the angiogenetic process and is involved in the pathophysiology of AMD. Anti VEGF therapies are used to treat wet-AMD. After diagnosis and explanations of the practionner, the patients and their close relatives have still frequently many questions about the intravitreal injections, the prognosis, the risk of visual impairment, etc. Few teams have studied the modalities of diagnosis announcement and the understanding of the patients on the disease course. The aim of this study is to evaluate the feelings after the AMD diagnosis announcement as well as the understanding of the possibilities of treatment and the clinical surveillance.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03035461
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Age Related Macular Degeneration
Currently open trials in the same condition.
- NCT07461441 — Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal · Phase 3 · recruiting
- NCT07235527 — Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degener · recruiting
- NCT07002372 — Effect of Video Viewing on Intravitreal Injection Experience · NA · recruiting
- NCT03102138 — Retinal Pigment Epithelium Safety Study for Patients in B4711001 · active not recruiting
- NCT05698316 — A Collaborative Resource of Heidelberg Multimodal Imaging of Intermediate and Early Atrophic AMD Cases to Study Predicti · active not recruiting
Other Centre Hospitalier Intercommunal Creteil trials
Trials by the same sponsor.
- NCT07493785 — Dexmedetomidine for Invasive Ventilation In the NEOnate · Phase 2, PHASE3 · not yet recruiting
- NCT07513051 — DIaphragmatic Swing According to Cpap Flow Output in NEOnates (DISCONEO) · NA · not yet recruiting
- NCT07455942 — Towards an Understanding of Barriers and Delays in the Diagnosis of Anal Cancer · not yet recruiting
- NCT07153367 — Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauter · Phase 2 · recruiting
- NCT06339450 — Real World Environmental Exposure Study With Healthy and Cystic Fibrosis Subjects · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03035461 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Intercommunal Creteil
- Last refreshed: 4 August 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03035461.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing